RxDoctor Payments DataLook up a doctor →

Georges Dahr, MD

Cardiovascular Disease · Millsboro, DENPI 1720089287

Payments from drug & device makers

$18,856in general payments, 2019–2025

Across 541 payments — averaging $34.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$8K
  • Pfizer$1K
  • Amgen$1K
  • Medtronic$987
  • AstraZeneca$902
  • Novartis$898
  • plus $6K from 43 others

What the payments were for

  • Speaking & faculty fees$6,53035%
  • Food & beverage$11,95363%
  • Education$3722%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,856 in reported general payments places this provider in the 80th percentile of 104 cardiovascular disease providers in Delaware.

See all cardiovascular disease providers in Delaware

Medicare billing

Part B allowed, 2024
$883,563
Medicare patients
2,283
Services billed
9,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban236$319,729
XareltoRivaroxaban102$135,149
EntrestoSacubitril/Valsartan37$70,113
JardianceEmpagliflozin38$58,602
Repatha SureclickEvolocumab20$31,936
Metoprolol Succinate642$10,821
Praluent PenAlirocumab12$10,806
Dabigatran EtexilateDabigatran Etexilate Mesylate17$5,239
Atorvastatin Calcium189$2,300
Amlodipine Besylate223$2,086
Nebivolol Hcl26$2,024
Rosuvastatin Calcium104$1,863
Losartan Potassium159$1,759
ClopidogrelClopidogrel Bisulfate122$1,644
Ezetimibe41$1,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,390$319,729236 claims
Johnson & JohnsonXarelto$701$135,149102 claims
NovartisEntresto$898$70,11337 claims
Boehringer IngelheimJardiance$7,662$58,60238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 104 cardiovascular disease providers in Delaware.

Other cardiovascular disease in Millsboro

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →